✓ Translated by DotMD AI Clinical Council Source: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #42736101 ↗

Phase III Randomized Trial: An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE)

Original Paper Title: “An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE)”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • A safety run-in with independent Data and Safety Monitoring Board review is planned during phase II to assess tolerance of the combination. Progression to phase III will depend on a predefined futility rule based on the ORR observed in the experimental arm.
  • Study Design & Sample: Phase III Randomized Trial published in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026), this phase iii randomized trial evaluating human clinical outcomes investigated: Patients with advanced hepatocellular carcinoma and high tumour burden (Vp4 PVTT, Vp3 PVTT with bilateral involvement, >50% liver involvement) have poor outcomes and are under-represented in major hepatocellular carcinoma trials (1,2). Key clinical takeaway: A safety run-in with independent Data and Safety Monitoring Board review is planned during phase II to assess tolerance of the combination. Progression to phase III will...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2026-11-15; Phase III Randomized Trial; Rigor 82/100): A safety run-in with independent Data and Safety Monitoring Board review is planned during phase II to assess tolerance of the combination. Progression to phase III will depend on a predefined futility rule based on the ORR observed in the experimental arm.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: durvalumab → Rx: tremelimumab → Rx: gemcitabine → Rx: oxaliplatin → Condition: cancer-living-with-cancer → Condition: cerebellar-disorders →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42736101: Phase III Randomized Trial: An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE)

3 of 3 Free Questions Remaining